Strategies for a Novel Liposomal Delivery Company
August 2007
Strategies for a Novel Liposomal Delivery Company
Interview with Elias Papatheodorou
Strategies for a Novel Liposomal Delivery Company
In this exclusive interview, Fintan Walton talks to Elias Papatheodorou, CEO of novosom, about the company’s novel liposomal technology, and the potential applications of this technology. Elias explains how novosom’s liposomes differ from those of competitors, and how the technology could provide an alternative to antibodies in the targeting of CD40 cells. The basis and strategy behind novosom’s agreements with Isis and other companies are also discussed. In addition, Elias talks about novosom’s current financing drive to fund the company’s activities.
About Elias Papatheodorou
Elias Papatheodorou joined novosom in September 2004 from ATI Medical Imaging, a New York-based medical imaging company, where he held the position of Vice President for marketing, sales and business development. During his tenure, the company signed multimillion agreements with companies such as Amgen, Janssen, J&J, Medicus, Medtronic, Novartis, CBS and Discovery Network, as well as other agreements with the US NIH, Siemens Medical and Zeiss. Elias was also involved in discussions with a number of leading pharmaceutical and biotechnology companies. Before ATI, Elias worked in various positions for The Coca-Cola Company and Philip Morris. He received his undergraduate education at Ithaca College, and his graduate education at Cornell University (both in New York).
About novosom
novosom is a biopharmaceutical company with a pioneering, fully charge-reversible liposomal technology for the delivery of DNA-based therapeutics. novosom's SMARTICLES® allow the delivery of siRNA, antisense or decoy oligonucleotides inside the cell for either topical or systemic applications.
In collaboration with its partners, novosom is developing unique therapeutics based on oligonucleotides in inflammation, oncology and liver diseases. In addition, the company is developing its own pipeline in autoimmune diseases, and is licensing its SMARTICLES technology for target validation approaches.
